

5 April 2022

ASX Announcement

Updated investor presentation and conference participation

MELBOURNE Australia, 5 April 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to release a copy of an investor presentation that will be delivered to investors over the coming weeks.

In addition, Island announces its participation in the inaugural PAC Partners Healthcare conference which takes place in Sydney, Australia this Wednesday 6 April 2022. During his presentation, Chief Executive Officer, Dr. David Foster will discuss the coming catalysts for Island as it moves lead drug candidate, ISLA-101 toward Phase 2 clinical trials for dengue fever.

Approved for release to the ASX by:

Dr Paul MacLeman Executive Chairman Island Pharmaceuticals Ltd info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe IR Department Mobile: +61 411 117 774 jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit <u>www.islandpharmaceuticals.com</u> for more on Island.

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia



Antiviral therapeutics

SOLVING URGENT VIRAL DISEASE THREATS

(ASX: ILA) PAC Partners Inaugural Healthcare conference – April 2022

DISCLAIMER



This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (**Company** or **Island Pharmaceuticals**).

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

Financial data All dollar values are in Australian dollars (\$ or A\$) unless otherwise stated. Any financial data in this presentation is unaudited. Past performance The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future performance

This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.



Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases


- Rapidly advancing lead drug ISLA-101 toward Phase 2 "PEACH"* clinical trial for the treatment of dengue fever
- Dengue fever infects +390 million people each year. There is currently no pharmaceutical treatment for the disease and limited access to only one vaccine
- Major market potential treating mosquito-borne diseases, exacerbated by climate change
- Priority Review Voucher potential for ISLA-101 at the time of FDA approval. PRVs have recently sold for at or slightly above US\$100m
- Pipeline expansion underway, targeting other viruses with significant unmet need and limited competition.

* PEACH: Phase 2a, randomized, double blind, placebocontrolled study for the Prophylactic Examination of an Antiviral in a Dengue Challenge Model.

THE BENEFITS OF DRUG REPURPOSING







- De novo · Low Success Rate Drug Discovery · Huge Cost and
- and Development Time-consuming Development

Drug Repurposing · Known Drug Safety

Reduced Pharmacokinetic Uncertainty





THE CHALLENGE





MOSQUITO BORNE VIRUSES: GLOBAL CHALLENGES





Upcoming mosquito season may be the worst yet. Here's how to prepare yourself

Australians are facing a brutal mosquito season bolstered by recent wet weather



Insect-borne viruses like Zika and Dengue could be the cause of the next pandemic, world health chiefs warn

- Viruses transmitted by insects could be next global pandemic WHO believes
- Pathogens like Zika virus are spread by arthropods like mosquitoes and ticks
- Nearly four billion people live in tropical and sub-tropical areas where they thrive

By MATT POWELL FOR MAILONLINE PUBLISHED: 07:02 AEDT, 1 April 2022 | UPDATED: 19:59 AEDT, 1 April 2022

UKTODAY

Chikungunya, Zika, and Dengue virusincidence in Mexico may be higherthan previously reportedDec 1, 2021



The researchers found 2.4 times the rate of arbovirosis as originally reported, including coinfections, suggesting underestimation of the incidence of the three viruses. However, future research is needed to provide up-to-date incidence estimates of each virus.





Porto Alegre issues epidemic alert for dengue, Zika virus and chikungunya at the end of the year

Colombia issues dengue fever alert

by NEWS DESK

Overset 14, 2021



Here's what we know about the Japanese encephalitis outbreak in Victoria, South Australia, NSW and Queensland

By Freya Michie and Sian Johnson Posted Wed 9 Mar 2022 at 1:52pm, updated Wed 9 Mar 2022 at 5:41pm



Rising dengue count a worry amid Covid Nov 17, 2021

If the number of dengue cases continues to rise, complications and fatalities due to the disease are prone to occur, they opine.

The Sydney Morning Herald

World Asia Timor-Leste

East Timor's hospitals are fighting a deadly outbreak, but it's not COVID



Save A Share A A

https://www.brytfmonline.com/porto-alegre-issues-epidemic-alert-for-dengue-zika-virus-and-chikungunya-at-the-end-of-the-year/ https://www.australiangeographic.com.au/topics/wildlife/2021/11/upcoming-mosquito-season-may-be-the-worst-yet-heres-how-to-prepare-yourself/ https://www.newindianexpress.com/cities/kochi/2021/nov/17/rising-dengue-count-a-worry-amid-covid-2384493.html https://www.abc.net.au/news/2022-03-25/queensland-japanese-encephalitis-cases-grow/100936884


https://www.smh.com.au/world/asia/east-timor-s-hospitals-are-fighting-a-deadly-outbreak-but-it-s-not-covid-20220202-p59t5t.html / https://www.dailymail.co.uk/news/article-10673727/Insect-borne-viruses-like-Zika-Dengue-cause-pandemic-warns.html

https://todayuknews.com/health/chikungunazika-and-dengue-virus-incidence-in-mexico-ang-bandemic-warns.html INVESTOR PRESENTATION – APRIL 2022

WHY DENGUE AS A FIRST TARGET FOR ISLA-101?

SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE





Significant unmet need (3.9 billion people at risk)

Increasing spread to US, EU and Australia

ISLA-101 has both therapeutic and prophylactic potential


Strong animal and human model results

First claim then springboard into other arboviruses

Priority Review Voucher eligibility


DENGUE IS A WIDESPREAD ISSUE





DENGUE IN 2050 – A GLOBAL DISEASE





Prediction based on projections of future temperatures, rainfall, and mosquito populations (NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford.)

LIMITED AVAILABLE SOLUTIONS



HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED





ISLA-101





ISLA-101 BROAD ACTIVITY EVIDENT



DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES (A SUBGROUP OF ARBOVIRUSES) IN MULTIPLE MODELS OF INFECTION




- In *in-vitro* models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity
- In animal models, ISLA-101 is protective in dengue fever and Zika
- In extremely lethal animal models, ISLA-101 was shown to prevent death in 70% of subjects
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection
- 45 HUMAN Clinical Studies of ISLA-101 completed in other indications

NEARING IND SUBMISSION



IND IS A CRITICAL REGULATORY MILESTONE, ENABLING PEACH STUDY COMMENCEMENT



Sponsor information (complete)

WORLD CLASS TEAM IN PLACE





Antiviral therapeutics

14

KEY COLLABORATIONS & ALLIANCES

SUPPORTING FUTURE PIPELINE DEVELOPMENT




MONASH University	Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed for use against Flaviviruses
Griffith UNIVERSITY Griffith Institute for Drug Discovery	Research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy. The small molecule libraries for Drug Discovery (GRIDD) Compounds Australia facility, using highly sensitive assays
AUSTRALIA	Research collaboration agreement signed with Australia's largest drug library containing millions of molecules that can be searched for drug re-purposing and pipeline development
	Cooperative Research and Development Agreement (CRADA) with the US Army in preparation for its Phase II clinical study for ISLA-101
Catalent.	Supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants
NIH NATIONAL CANCER INSTITUTE	Right to reference National Cancer Institute IND for Isla-101

PATHWAY / TIMING TO CLINICAL TRIALS







PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL



"PEACH" STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY Antiviral therapeutics FOR THE **P**ROPHYLACTIC **E**XAMINATION OF AN **A**NTIVIRAL IN A DENGUE **CH**ALLENGE MODEL

Phase II trial protocol

Up to 4 cohorts/4 arms

Inclusion

- Healthy subjects
- Age 18-45
- Willing to use contraception for the duration of the study
- Informed consent

Exclusion

- Female: pregnant or lactating
- Prior infection with HIV, HCV, Flaviviruses
- Current, or a history of, autoimmune disease


Primary endpoint

 Assess the prophylactic effect of ISLA 101 on fever, clinical symptoms, laboratory abnormalities and viremia after challenge with DENV-1-LVHC

Secondary endpoints

- Characterise the clinical, immunologic and virologic responses following ISLA 101 after challenge with DENV-1-LVHC
- Assess the safety of ISLA 101 in the challenge with DENV-1-LVHC

Administer ISLA-101 daily





The study will be run at SUNY Upstate Medical University Syracuse, New York


THE COMMERCIAL OPPORTUNITY





COMMERCIAL OPPORTUNITY





Tropical area travellers opportunity:

- Comparable to malaria market expected to reach US\$1B in 2026*
- Increasing numbers of countries due to global warming

Military opportunity:

- Isla is partnering with army (CRADA in place) for Phase 2a clinical trial in Dengue Fever
- We will pursue a contract with the military as we get closer to approval

Endemic area opportunity:

- Many millions of patients in Central and South America
- Potential for sales for disease suppression and treatment during outbreaks
- Potential for endemic countries to establish and maintain drug stockpiles as happens with influenza

ADVANCING OUR PIPELINE



Island has recently engaged a third party virologist to investigate ~150 human relevant viruses, prioritised by:

Medical relevance for the Americas, Europe, Australia/NZ

Significant unmet need

Limited competition

Insight into virus mechanism/life cycle

Exemplary viruses that met these criteria include:

- Zika virus
- Human respiratory syncytial virus
- Human rhinovirus
- Echovirus
- Human adenovirus
- Human cytomegalovirus
- Coxsackievirus
- Hepatitis delta virus





Under collaborations with Monash and Griffith Universities, Island is further evaluating next viruses to investigate.

UPCOMING MILESTONES



H1 FY 2022 H2 FY 2022 H1 FY 2023

- ✓ Sign SUNY CTA
- Announce Principal Investigator
- ✓ Engaged CRO
- Drug substance (API) manufactured
- Advance research collaboration

- Drug substance manufactured
- Analytical method development
- Preliminary timeframe for clinical product manufacturing

- File IND
- Open IND
- Start screening subjects for PEACH* trial
- First subject in PEACH trial
- Advance through PEACH cohorts

- Advance through PEACH cohorts
- Trial read out
- Meeting with FDA
- Identify lead molecules from research collaborations

* PEACH: Phase 2a, randomized, double blind, placebocontrolled study for the Prophylactic Examination of an Antiviral in a Dengue Challenge Model.

BOARD, MANAGEMENT & SCIENTIFIC BOARD



MANAGEMENT TEAM & BOARD OF DIRECTORS









Mr. Al Hansen Director



Dr. Paul MacLeman **Executive Chair**

Dr. David Foster **CEO & Executive** Director

Dr. Anna Lavelle Non-Executive Director

Non-Executive

Dr. David Brookes **Non-Executive Director**



Assoc. Prof. Leigh Farrell





Prof. Stephen Thomas MD



Dr. Simon Tucker



David Foster Chief Executive Officer & Executive Director david@islapharma.com

Authorized for release by Paul MacLeman, Executive Chairman

www.islapharma.com Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia Approved for release by Paul MacLeman **Island Pharmaceuticals**

Limited ACN 641 183 842